Therapies (HBV)

Treatment with Nucleoside Analogue Followed by Hepatitis Vaccine Shifts Serologic Phenotype

Published in Cancer Weekly, July 18th, 2000

Treatment with the nucleoside analogue, L-FMAU, followed by vaccination changed hepatitis B infection status from chronic to recovering in the WHV/woodchuck model, researchers in the United States reported.

"Previous studies in the woodchuck model of HBV infection have demonstrated that the nucleoside analogue, L-FMAU, had potent antiviral activity," said J. Gerin and colleagues from the Georgetown University Medical Center, Maryland, and Cornell University, New York. "Treatment of chronic carriers had a profound effect on levels of virus and surface antigen (WHsAg) with continued suppression of these markers following drug withdrawal.

"Accordingly,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-07-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry